Sg3 Management, LLC Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Sg3 Management, LLC

  • $0
  • Q3 2023

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$25.35 - $31.96 $760,500 - $958,800
30,000 New
30,000 $946,000
Q2 2022

Aug 15, 2022
SELL
$20.62 - $37.15 $515,500 - $928,750
-25,000 Reduced 71.43%
10,000 $264,000
Q1 2022

May 16, 2022
BUY
$23.5 - $35.38 $822,500 - $1.24 Million
35,000 New
35,000 $1.23 Million

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Sg3 Management, LLC Portfolio

Follow Sg3 Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email